Brand Name | Status | Last Update |
---|---|---|
hemlibra | Biologic Licensing Application | 2023-07-11 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
hemophilia a | EFO_0007267 | D006467 | D66 |
Expiration | Code | ||
---|---|---|---|
emicizumab, Hemlibra, Genentech, Inc. | |||
2025-10-04 | Orphan excl. |
Code | Description |
---|---|
J7170 | Injection, emicizumab-kxwh, 0.5 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hemophilia a | D006467 | EFO_0007267 | D66 | 4 | 2 | 13 | 7 | 14 | 40 |
Immune tolerance | D007108 | — | — | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Type 3 von willebrand disease | D056729 | Orphanet_166096 | D68.03 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Thrombosis | D013927 | — | — | — | — | — | — | 1 | 1 |
Thrombophilia | D019851 | — | D68.59 | — | — | — | — | 1 | 1 |
Von willebrand diseases | D014842 | EFO_0003910 | D68.0 | — | — | — | — | 1 | 1 |
Drug common name | Emicizumab |
INN | emicizumab |
Description | Emicizumab, sold under the brand name Hemlibra, is a humanized bispecific monoclonal antibody for the treatment of haemophilia A, developed by Genentech and Chugai (a subsidiary of Hoffmann-La Roche). A Phase I clinical trial found that it was well tolerated by healthy subjects.
|
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL3833393 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB13923 |
UNII ID | 7NL2E3F6K3 (ChemIDplus, GSRS) |